To evaluate the relative efficacy of ciclosporin (CsA) and sodium hyaluronate (SH) eye drops in treating diabetes-related dry eye syndrome (DMDES) after vitrectomy, addressing a significant gap in current postoperative management.
Key Findings:
CsA group showed greater improvements in NIBUT, TMH, and SIT at 1 month compared to SH group, indicating enhanced tear film stability.
CsA group had lower CFSS scores indicating less corneal epithelial damage over time, suggesting better ocular surface health.
Age and gender did not significantly affect outcomes, reinforcing the robustness of the findings.
Interpretation:
0.05% CsA eye drops were associated with improved tear film quality and stability after vitrectomy for DMDES, showing better relative improvement compared to SH eye drops, which may influence treatment choices in clinical practice.
Limitations:
Retrospective design may introduce selection bias; future studies should consider a randomized controlled trial.
Single-center study limits generalizability; multicenter studies are recommended.
Lack of long-term follow-up data; future research should include extended follow-up to assess long-term efficacy.
Conclusion:
Ciclosporin eye drops may be more effective than sodium hyaluronate in managing DMDES post-vitrectomy, suggesting a potential preference for CsA in clinical practice to enhance patient outcomes.
This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.
